FINCH 1 Trial Filgotinib in Rheumatoid Arthritis The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the JAK1 preferential inhibitor filgotinib was superior to adalimumab in active RA on MTX. https://t.co/d501qhArfP https://t.co/YGH5LQDGbs